Key result
Higher ePWV is linked to ~49% higher odds of moderate liver fibrosis.
Why the study?
Noninvasive tools for integrated assessment of MAFLD and early fibrogenesis remain limited, motivating investigation of ePWV's association with hepatic steatosis and liver fibrosis.
Cross-Sectional (n=1,116)
Yes
Odds Ratio: 1.494 (95% CI 1.248–1.789)
p-value: p=<0.001
Estimated pulse wave velocity (ePWV) exhibits a nonlinear association with MAFLD and liver fibrosis, suggesting it may serve as an accessible, non-invasive surrogate marker of metabolic liver disease progression in primary care.
Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) and its progressive complication, liver fibrosis, have emerged as global public health burdens. Noninvasive tools for integrated assessment of MAFLD and early fibrogenesis remain limited. This study investigated the association between estimated pulse wave velocity (ePWV) and hepatic steatosis/liver fibrosis and assessed ePWV's utility in evaluating these conditions. Methods: This cross-sectional study included participants from Shanghai community health centers (March-November 2021) as part of a nationwide MAFLD screening project, "Screening of Metabolic Associated Fatty Liver Disease." Demographic data, medical history, and laboratory/imaging results were collected. Multiple logistic regression and restricted cubic spline (RCS) curves identified associations between ePWV and MAFLD/liver fibrosis. Results: A total of 1,116 participants from four community health service centers in Shanghai were enrolled. Among them, 613 had no MAFLD, 232 had light, 202 had moderate and 69 had severe MAFLD, while 886 had no liver fibrosis, 172 had light, 52 had moderate, and six had severe liver fibrosis. Participants with MAFLD or liver fibrosis exhibited higher ePWV values and demonstrated increasing trends across disease severity categories. RCS analyses revealed nonlinear associations between ePWV and both MAFLD and liver fibrosis. When ePWV exceeded 13.26 m/s, the odds ratios (ORs) for MAFLD and liver fibrosis were consistently greater than 1. Conclusions: ePWV showed nonlinear associations with MAFLD and liver fibrosis. Values above 13.26 m/s were associated with higher odds of both conditions, suggesting that ePWV may serve as a practical vascular marker of hepatic metabolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) conducted a cross-sectional in Metabolic dysfunction–associated fatty liver disease (MAFLD) and liver fibrosis (n=1,116). Estimated pulse wave velocity (ePWV) vs. Lower ePWV / Participants without MAFLD or liver fibrosis was evaluated on Moderate liver fibrosis (vs no liver fibrosis) (OR 1.494, 95% CI 1.248-1.789, p=<0.001). Higher estimated pulse wave velocity demonstrated a nonlinear association with hepatic steatosis and liver stiffness, with ePWV values above 13.26 m/s significantly increasing the odds of both MAFLD and liver fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: